📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2. (2022)

First Author: Walker LE

Attributed to: An Injectable Implant Providing Long-Acting Drug Delivery for the Treatment of Chronic disease funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1002/cpt.2463

PubMed Identifier: 34699618

Publication URI: http://europepmc.org/abstract/MED/34699618

Type: Journal Article/Review

Volume: 111

Parent Publication: Clinical pharmacology and therapeutics

Issue: 3

ISSN: 0009-9236